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Objectives: The objectives of this study were to examine factors predictive of success or failure after percutaneous
angioplasty (PTA) and stenting (S) of the superficial femoral artery (SFA) and to compare the results of PTA/S with a
contemporary group of patients treated with femoropopliteal bypass.
Methods: A database of patients undergoing PTA and/or S of the SFA between 1986 and 2004 was maintained.
Intention-to-treat analysis was performed. Patients underwent duplex scanning follow-up at 1, 3, and every 6 months
after the intervention. Angiograms were reviewed in all cases to assess lesion characteristics and preprocedure and
postprocedure runoff. Results were standardized to current TransAtlantic Inter-Society Consensus (TASC) and Society
for Vascular Surgery (SVS) criteria. Kaplan-Meier survival analyses were performed to assess time-dependent outcomes.
Cox proportional hazard analyses were performed to assess factors associated with patient survival and treatment efficacy.
Results: Three hundred eighty total limbs underwent PTA/S in 329 patients (67% male, 33% female; average age, 65
years). Mean follow-up was 1.8 years from the date of initial intervention. Indications for intervention were claudication
in 66%, rest pain in 16%, and tissue loss in 18%. Runoff at the tibial level was 2.1 0.8 patent vessels. Mean SVS ischemia
grade was 3.1 (range, 1 to 5). TASC lesion grades were A (48%), B (18%), C (22%), and D (12%). Angioplasty alone was
used in 63% of cases. Primary treatment failure (inability to cross lesion) was seen in 7% of patients. There was one
periprocedural death. Primary patency rates were 86% at 3 months, 80% at 6 months, 75% at 12 months, 66% at 24
months, 60% at 36months, 58% at 48months, and 52% at 60months. Assisted primary patency rates were slightly higher
(P  not significant). By Cox proportional hazards analysis, patency of PTA/S was associated with higher preoperative
ankle/brachial index (P  .016) and the performance of angioplasty only (P  .011). Failed or occluded PTA/S was
associated with TASC C (P < .0001) and TASC D lesions (P < .0001). Patient death was associated with the presence
of congestive heart failure (P  .003). Subgroup analysis revealed that primary patency rates are highly dependent on
lesion type (A> B>C>D, P< .0001). PTA/S patency for TASC A and B lesions compared favorably to prosthetic and
venous femoropopliteal bypass. Surgical bypass was superior to PTA/S for TASC C and D lesions.
Conclusions: PTA and stenting of the SFA can be performed safely with excellent procedural success rates. Improved
patency of these interventions was seen with increased ankle/brachial index and the performance of angioplasty only.
Worse patency was seen with TASC C and TASCD lesions. Patency rates were strongly dependent on lesion type, and the
results of angioplasty and stenting compared favorably with surgical bypass for TASC A and B lesions. ( J Vasc Surg
2005;41:269-78.)Occlusion of the superficial femoral artery (SFA) can
lead to claudication and can contribute to chronic critical
ischemia. For patients with claudication, aggressive risk
factor modification and exercise programs are recom-
mended, and interventions are reserved for failures of this
therapy. For critical ischemia, revascularization, if possible,
is standard of care. During the last few years the treatment
of SFA occlusive disease has undergone a shift in manage-
ment within these paradigms to include more aggressive
endoluminal therapy. Reports from the 1980s and 1990s
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doi:10.1016/j.jvs.2004.11.031suggested that SFA angioplasty is an adequate short-term
intervention, but that long-term patency is poor. Four
randomized trials1-4 have shown that primary stenting has
no added benefit. However, stent design has continued to
change since the completion of the randomized trials.
Lesion type based on the TransAtlantic Inter-Society Con-
sensus (TASC) criteria will also effect patency, with TASC
A appearing to be very suitable for endoluminal therapy,
whereas TASC D lesions are most suitable for bypass.5
Optimal therapy for TASC B and C lesions remains unde-
cided.5 The factors that are predictive of the success or
failure of these interventions remain to be defined. This
report outlines the unique and extensive experience of a
combined surgery and interventional radiology program at
the University of Rochester with percutaneous translumi-
nal angioplasty and stenting for symptomatic atheroscle-
rotic SFA occlusive disease using an aggressive treatment
strategy.
METHODS
Experimental design/setting. A database of patients
undergoing percutaneous angioplasty (PTA) and/or stent-
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at the University of Rochester. Immediate technical failures
were identified and included to allow for an intention-to-
treat analysis. For each patient, demographics, symptoms,
existing comorbid conditions, and risk factors for athero-
sclerosis were identified. Angiograms and angiographic re-
ports were reviewed, lesions were categorized under the
TASC system, and the runoff was scored. All patients
received anti-platelet therapy; 2% were on warfarin at the
time of the intervention, and this was continued after the
procedure. All patients with claudication were encouraged
to exercise daily, and their risk factors were identified and
corrected through their primary care providers. Those pa-
tients who did not improve on these regimens were offered
endoluminal intervention. Patients with critical ischemia
were treated expeditiously. Therapy for individual patients
was dictated by individual attending physician preference
and was not regulated by unit guidelines. Median patient
follow up was 1.8 years (range, 0 to 11 years). Follow up
within 3 months was available in 88% of cases. Patients
underwent routine duplex scanning follow-up at 1, 3, and
every 6 months after the PTA/S procedure. Progression of
proximal or distal disease was confirmed by angiography in
all cases. Procedures to maintain patency and any proce-
dures performed after occlusion of the index segment were
recorded.
PTA/S procedure. All PTA/S procedures were per-
formed in our fixed-imaging operating room suite or in our
interventional radiology suites. A standard aortogram and
runoff were performed with a power injector. Carbon di-
oxide and/or gadolinium were used for patients with se-
rum creatinine levels of 1.5 mg/dL or higher. Access to the
SFA was obtained from either an antegrade, ipsilateral
approach or via an up-and-over Balkin sheath (Cook Inc,
Bloomingdale, Ind) from the contralateral groin. Angio-
plasty was performed under systemic heparin administra-
tion (40 to 60 U/kg), and completion angiography was
performed to assess the technical result. Stents were used
(at the discretion of the operator) for flow-limiting dissec-
tions, intimal flaps, or poor technical results. In general, for
TASC C and D lesions, primary stenting was used. For
complete occlusions, an 0.035-inch glide wire (Boston
Scientific, Natick, Mass) through a 4-5F glide catheter
(Boston Scientific Corp) was used to traverse the occlusion.
Re-entry into the native arterial lumen downstream was
confirmed via contrast injection. Self-expanding nitinol
stents (various manufacturers) were then used preferen-
tially to re-establish a flow lumen for complete occlusions.
A GP IIb/IIIa inhibitor (abciximab 3.75 g/kg/h for 12
hours) was used at the discretion of the primary operator
when thought to provide benefit. In general, groin closure
was accomplished via manual compression.
Concurrent open femoropopliteal bypass group.
To serve as a comparison, a database was maintained for all
patients undergoing open femoropopliteal bypass at the
University of Rochester during the time period 1989 to
2004. Three hundred fifty patients underwent femoral
above-knee or below-knee bypass with prosthetic (polytet-rafluoroethylene or Dacron), and 316 underwent femoral
above-knee or below-knee bypass with a venous conduit
during this time period. In general, for the venous proce-
dures, reversed saphenous vein was the conduit of choice.
Definitions. Coronary artery disease was defined as a
history of angina pectoris, myocardial infarction, conges-
tive heart disease, or prior coronary artery revasculariza-
tions. Chronic renal impairment was defined as a serum
creatinine level of 1.5 mg/dL (132.6 mol/L) or greater
or a patient on peritoneal or hemodialysis. Cerebrovascular
disease included a history of stroke, transient ischemic
attack, or carotid artery revascularization. Hypertension
was defined as a systolic blood pressure greater than 150
mmHg or diastolic blood pressure greater than 90 mmHg
on three occasions during a 6-month period. Hypercholes-
terolemia was defined as fasting cholesterol 200 mg/dL,
a low density lipoprotein 130 mg/dL, or triglycerides
200 mg/dL. Diabetes was defined as a fasting plasma
glucose 110 mg/dL or a hemoglobin A1c 7%.
TASC classification of disease severity for femoral le-
sions was used to define the categories of the lesions. TASC
A lesions denote single stenoses up to 3 cm in length. TASC
B lesions denote single stenoses or occlusions 3 to 5 cm in
length, heavily calcified lesions up to 3 cm in length,
multiple lesions each less than 3 cm, or lesions in the
absence of continuous tibial runoff. TASCC lesions denote
single stenosis or occlusion greater than 5 cm, or multiple
lesions, each 3 to 5 cm, with or without calcium. TASC D
lesions denote complete common femoral or SFA occlu-
sions and complete popliteal or proximal trifurcation occlu-
sions.
A procedural success was defined by a residual stenosis
of 30% without complications of either distal embolism
or in situ thrombosis and by the SVS/American Heart
Association (AHA) scale (–3 to 3); primary failures were
defined as residual stenosis 30% by angiographic mea-
surement and included lesions unable to be dilated or
crossed. A death within 30 days of the procedure was
considered procedure-related. A major complication was
defined as any event, regardless of how minimal, not rou-
tinely observed after endoluminal therapy that required
treatment with a therapeutic intervention or rehospitaliza-
tion within 30 days of the procedure. Runoff at the tibial
level was determined by the number of patent vessels
present with a maximum of 3 (scored as 0, 1, 2, or 3).
Primary patency was defined as a patent SFA segment
without recurrent stenosis or the need for further interven-
tion. Assisted primary patency was defined as a patent SFA
segment that underwent further intervention within the
inflow, treated vessel segment, or outflow of the treated
vessel segment to improve patency. Secondary patency was
defined as an occluded SFA vessel or an SFA with hemody-
namic failure resulting in a surgical bypass. Loss of patency
was defined according to accepted reporting standards.
Preprocedural and postprocedural symptoms were defined
by SVS criteria, and a decrease of one or greater in
follow-up was considered as recurrent symptoms.
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(S.W.E.) performed all statistical analyses on an intention-
to-treat basis. Measured values are reported as percentages
or means  1 standard deviation. Survival, cumulative
primary patency, primary assisted patency, secondary pa-
tency, limb salvage, and clinical benefit rates were calcu-
lated by using Kaplan-Meier analysis and reported by using
current SVS criteria.5 Standard errors were reported in
Kaplan-Meier analyses. The log-rank test was used to de-
termine differences between life tables. Analyses were per-
formed with SAS software version 8.2 (SAS Institute, Cary,
NC). Multivariate stepwise regression analysis was used to
determine the influence of preprocedural and periproce-
dural factors on outcomes. The significance level P  .10
was used to include or eliminate a covariate from the
model. Covariates were considered to be significantly asso-
ciated with the outcome, if they were included in the final
model and their significance level was P .05. Interactions
between statistically significant covariates were checked.
The Cox proportional hazards model was used for time-
dependent outcomes (mortality, patency, restenosis, long-
term freedom from symptoms). The proportional hazards
assumption was checked and confirmed for the significant
covariates by using log (–log (survival)) curves. Logistic
regression models were used for outcomes measured
shortly after the procedure (complications, short-term clin-
ical benefits). The dependence of each covariate on the
outcome was first checked separately by using the 2 test.
Covariates with the significance level of P .10 were in-
cluded in the multivariate stepwise analysis.
RESULTS
PTA/S patient population. Three hundred twenty-
nine patients (33% female; age, 65 11 years, range, 32 to
87 years) underwent 380 SFA PTA/S procedures. Charac-
teristics of the patients are shown in Table I. Nine percent
of patients were on hemodialysis. Sixty-six percent of the
patients presented with claudication and 34% with critical
ischemia (16% with rest pain and 18% with tissue loss).
Patient survival by life-table analysis was 94% and 86% at 1
and 5 years, respectively.
Anatomy. The distribution of disease and severity of
disease in each vessel segment are shown in Table II.
Sixty-two percent of lesions were TASC category A and
22% category B, 18% category C, and 11% category D.
Runoff at the tibial level was 2.1  0.8 patent vessels. The
number and anatomic distribution of stents deployed are
also shown. All patients received heparin during the proce-
dure, and 8% also received a GPIIb/GPIIIa inhibitor for 12
hours after the procedure. Five percent required thrombol-
ysis for in situ thrombosis or distal embolization. Concom-
itant ipsilateral iliac and tibial interventions were performed
in 2% of cases to improve inflow or outflow.
Immediate outcomes. Three hundred eighty primary
interventions were performed, and 37% included place-
ment of stents. Technical success (defined by 30% resid-
ual stenosis) was achieved in 93% of vessels. Primary treat-
ment failure (inability to cross lesion) was seen in 7% ofpatients. During the procedure there were significant tech-
nical complications in 9% of cases requiring adjuvant en-
doluminal therapy (intimal flap, 1%; uncontrolled dissec-
tion, 5%; perforation, 3%). The postprocedure-related
complication rate was 10% (embolization, 3%; groin hema-
toma/bleeding, 5%; pseudoaneurysm, 2%; arteriovenous
fistula, 1%). One patient died as a result of a ruptured iliac
artery at the time of PTA/S. There were no other peripro-
cedural deaths. Immediate hemodynamic success (defined
as an increase in ankle/brachial index [ABI] 0.15) was
achieved in 71%. The average SVS composite technical
success grading was 1.8  1.2.
Intermediate outcomes. The average symptom score
(SVS scale, 0 to 6; 0, no symptoms and 6, major tissue loss)
was 3.2 1.2 before intervention, and this improved to 1.8
 1.3 after intervention. Within 1 month, 81% of patients
exhibited clinical improvement (a decrease by one or more
points) with the SVS criteria.
Longer-term outcomes. Considering all lesions, pri-
mary patency was 75%, 66%, 60%, and 50% at 1, 2, 3, and 6
years, respectively. Assisted primary and secondary patency
rates were similar to primary patency rates (P  not signif-
icant, curves not shown for clarity). Limb salvage was 84%,
77%, and 70% at 1, 3, and 6 years, respectively. Limb
salvage rates were calculated separately for claudication and
critical limb ischemia, and there was a significant difference
between the two groups (Table III). There were 39 above/
below knee amputations (10% of limbs at risk). Patients
with above/below knee amputation had a presenting SVS
limb ischemia score of 4.1  1.2 and tibial runoff of 1.5 
Table I. Patient characteristics and indications for
intervention
Characteristic PTA/S P V
Total patients 329 350 316
Male 70% 56% 58%
Female 30% 44% 42%
Mean age (y) 65 76 76
History of previous myocardial
infarction
50%
Congestive heart failure 26%
Hypertension 78%
IDDM 25%
NIDDM 33%
Hyperlipidemia 56%
Statin use 48%
Cerebrovascular disease 18%
Chronic renal insufficiency
(creatinine  1.5 mg/dL)
28%
Hemodialysis 9%
Indication for intervention
Claudication 66% 49% 32%
Rest pain 16% 21% 21%
Tissue loss 18% 30% 32%
PTA/S, Angioplasty and stent population; P, prosthetic femoropopliteal
bypass population; V, femoropopliteal with autogenous vein bypass popu-
lation; IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-
dependent diabetes mellitus.0.8 vessels. Eighteen additional limbs underwent digit or
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broken down by lesion type, the results of PTA/S were
highly lesion dependent (P .0001), with TASC A lesions
having the best outcomes and TASC D lesions having the
poorest. Six-month primary patency rates were 90% (95%
confidence interval, 84%-94%) for TASC A lesions, 85%
(75%-93%) for TASC B lesions, 70% (58%-82%) for TASC
C lesions, and 50% (37%-70%) for TASC D lesions. As can
be seen in the figures, follow-up is shorter for TASC C and
D lesions, because we have only recently been attempting
PTA/S on these lesions.
Risk factor analysis. Cox proportional hazards analy-
Table II. Disease characteristics and procedural data,
PTA/S patients only
Characteristic n %
TASC lesion category
A 181 48
B 84 22
C 69 18
D 42 11
SVS limb ischemia grade
1, mild claudication 19 5
2, moderate claudication 103 27
3, severe claudication 123 32
4, rest pain 62 16
5–6, tissue loss 74 19
Concurrent thrombolysis 19 5
Preprocedure tibial runoff
(no. patent tibial vessels)
0–1 101 26
2–3 277 74
Mean ABI, affected limb 0.38  0.3
Stent placement
Angioplasty only 241 63
Stent 139 37
Avg no. stents/patient 2.1
Stent location
Proximal SFA 17
Mid-SFA 28
Distal SFA 39
BK/AK popliteal 16
Postoperative data
SVS technical success grade 1.8  1.2
Mean ABI change 0.21  0.2
ABI change  0.15 71
BK, Below-knee; AK, above-knee.
Table III. Limb salvage rates by presenting symptoms:
Claudication vs critical limb ischemia (CLI)
Time Claudication CLI P value
6 mo 99  1 (260) 72  3 (145) .05
1 y 99  1 (156) 77  5 (63) .05
3 y 95  2 (60) 67  10 (15) .05
5 y 90  5 (31) 67  12 (11) n/a
Values are mean  standard error. The number in parentheses represents
number at risk for each interval. A P value was not calculated for the 5-year
interval because of the small number of patients available at this interval. All
other values were statistically significant.sis was performed to identify the influence of preproceduraland periprocedural factors on mortality and patency. These
results are shown in Table IV. The presence of congestive
heart failure (hazard ratio, 8.6; 95% confidence interval,
2.1-35.5) was found to be significantly associated with
increased mortality. Age, gender, smoking status, hyper-
tension, diabetes, and hyperlipidemia were not found to be
associated with an increased risk of mortality. Table IV
shows factors associated with loss of patency after PTA/S.
TASC C (hazard ratio, 3.0; 95% confidence interval, 1.4-
6.1) and TASC D (hazard ratio, 4.4; 95% confidence
interval, 1.8-10.5) lesions were found to have an associa-
tion with anatomic failure. Higher preprocedure ABI and
the performance of angioplasty only were found to be
protective from loss of patency (hazard ratios 1). There
was no difference in outcomes (patency or limb salvage)
between patients in whom primary stenting was used com-
pared to those in whom selective stenting was used. When
these data on primary versus selective stenting were strati-
fied by TASC lesion, there was again no significant differ-
ence in outcomes.
Comparison with femoropopliteal bypass.
Characteristics of the open bypass patients are also shown in
Table I. These patients were 10 years older than the PTA/S
patients (average age, 76 years for open bypass patients
versus 65 years for PTA/S patients), and the gross inci-
dence of tissue loss was 10% higher (30% for open bypass
patients vs 20% for PTA/S). Fig 1 shows the results of open
standard femoropopliteal bypass with prosthetic (polytet-
rafluoroethylene or Dacron) at the University of Rochester
compared to the results of PTA/S broken down by lesion
type. As can be seen in the figure, the patency of prosthetic
femoropopliteal bypass is close to that of PTA/S for TASC
B lesions out to 5 years. Fig 2 shows the results of open
femoropopliteal bypass with autogenous vein at the Uni-
versity of Rochester compared to the results of PTA/S
broken down by lesion type. As can be seen in the figure,
the patency of femoropopliteal bypass with vein is close to
that of PTA/S for TASC A lesions out to 5 years. The
patency of TASC C and D lesions appears much worse than
open femoropopliteal bypass with vein or prosthetic.
Symptomatic improvement. Fig 3 shows the entire
PTA/S population and freedom from recurrent symptoms.
Symptom relief rates were 87%, 72%, and 62% at 1, 4, and 6
years, respectively.
DISCUSSION
The current study has shown that PTA/S of the SFA
can be performed with minimal morbidity and is associated
with reasonable patency rates in TASC A and TASC B
lesions. It is important to note that survival was better in
our patient population (94% and 86% at 1 and 5 years,
respectively) than in previously reported large-scale series of
claudicants.6 The reason for the improved survival noted in
the series might be related to the younger age of our
PTA/S patients (compared to the open bypass patients)
and the improved medical care of these patients. Limb
salvage rates were also reasonable at 70% 6 years after the
intervention. The presence of congestive heart failure was
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ing PTA/S. Although it is impossible to draw a cause-and-
effect relationship, few studies have mentioned contraindi-
cations to endoluminal therapy. On the basis of our data,
the presence of congestive heart failure might signal cau-
tion when attempting prolonged PTA/S procedures.
In this study the results of PTA/S were highly depen-
dent on lesion type. The TASC5 recommended the use of
angioplasty for TASC A lesions and surgical bypass for
TASC D lesions. They suggested that further study was
necessary for TASC B and C lesions. The results of this
study suggest that endoluminal therapy might be appropri-
ate for TASC B lesions as well. In a recent report, Costanza
et al7 retrospectively reviewed 115 limbs in 98 patients after
PTA/S of only TASC B lesions at a median follow-up of 10
months by using duplex ultrasound scanning. They re-
ported that restenosis occurred in 45% of patients at 1 year
and concluded that “the length of time that a treated
arterial segment remains free of stenosis is limited.” We did
not see as much restenosis in our TASC B lesions, which
had a primary patency of 83% at 12 months. The reason for
our lower restenosis rate is unclear.
The results of PTA/S for TASC C and D lesions were
much worse than those of open surgical bypass. Primary
patency failure was seen in one half of TASC D lesions
treated with PTA/S by 9months after the procedure and in
one half of TASC C lesions by 18 months after the proce-
dure. Exuberant intimal hyperplasia remains a problem in
long SFA occlusions. Newer treatment strategies combined
with pharmacologic means of preventing or treating the
Table IV. Proportional hazards and logistic regression mo
Patient characteristic
Factors associated with increased risk of mortality
Age  65 y 
Gender
Stopped smoking 
Now smoking
Congestive heart failure
Hypertension
Insulin-dependent diabetes mellitus
Non–insulin-dependent diabetes
Hyperlipidemia
Statin use
Factors associated with loss of patency
Preprocedure ABI >0.4
TASC B lesion
TASC C lesion
TASC D lesion
SVS ischemia grade 2
SVS ischemia grade 3
SVS ischemia grade 4
SVS ischemia grade 5
Tibial runoff
Thrombectomy
Angioplasty only
Factors that are statistically significant are indicated by bold print.intimal hyperplastic response are needed to improve thedurability of these interventions. Drug-eluting stents
and/or cryoplasty might ultimately be of benefit. Cryo-
plasty is a novel therapy that combines conventional bal-
loon angioplasty with application of cold-induced injury to
the vessel wall, hopefully inducing apoptosis in the smooth
muscle cells of the injured vessel. The final results of the
cryovascular safety registry8 have shown a primary patency
of 82% in 102 patients at 10 months. Duda et al9 performed
a randomized trial comparing the use of sirolimus-eluting
SMART (shapememory alloy recoverable technology) niti-
nol stents versus uncoated SMART nitinol stents in 36
patients with chronic limb ischemia and femoral artery
occlusions (57%) or stenoses. At 6 months, angiography
revealed an in-stent mean lumen diameter of 4.95 mm in
the sirolimus group versus 4.31 mm in the uncoated stent
group. The unexpected finding of this study was that the
restenosis rates in the uncoated nitinol stents were much
lower than what had been expected, giving hope that SFA
outcomes will improve as stent technology continues to
evolve. Coated stents are not currently available for use in
the peripheral circulation in the United States.
Decisions to treat SFA occlusions are increasingly being
made irrespective of primary patency rates alone. Quality of
life issues are increasingly taken into account when discuss-
ing treatment options with patients. Decisions to proceed
with angioplasty and stenting of the SFA for TASCC andD
lesions will continue to be made. Reasons usually include
patient or provider preference for minimally invasive treat-
ments, the fact that surgery can usually proceed in similar
fashion after failed endoluminal intervention, short-term
(PTA/S patients only)
Hazard ratio
(95% confidence interval) P value
0.86 (0.20–3.74) .85
2.03 (0.48–8.50) .33
1.97 (0.18–21.08) .57
2.71 (0.16–45.97) .49
8.56 (2.06–35.51) .003
0.28 (0.062–1.24) .09
4.50 (0.89–22.75) .07
2.00 (0.38–10.64) .42
1.92 (0.49–7.56) .35
2.21 (0.58–8.42) .25
0.47 (0.25–0.87) .016
1.16 (0.55–2.42) .70
2.95 (1.42–6.14) .004
4.40 (1.84–10.51) .0008
1.64 (0.49–5.50) .42
1.44 (0.42–4.93) .57
1.13 (0.30–4.25) .85
2.69 (0.76–9.51) .13
0.84 (0.62–1.14) .27
1.24 (0.54–2.84) .60
0.43 (0.22–0.84) .014delstissue healing goals, patients deemed too high risk for open
(poly
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site. Quality of life studies will need to be performed to
assess the ultimate benefit to the patient in regards to these
issues.
In our study the presence of TASC C and TASC D
lesions, higher presenting limb ischemia grade, and conges-
tive heart failure were associated with failure of PTA/S. A
higher preoperative ABI and the performance of angio-
plasty only were associated with improved results of
PTA/S. These results all suggest that advanced levels of
disease portend poorer results with the currently available
technology.Multiple factors have previously been shown to
adversely affect patency of PTA/S including presenting
symptoms (claudication vs critical ischemia), type of lesion
(stenosis vs occlusion), length of lesion (10 cm and 10
cm), and distal runoff.10-13 Patients with diabetes have
been shown to have worse outcomes than patients without
diabetes.11,14 Patients treated for critical ischemia have
lower patency rates than patients treated for claudication.
Fig 1. Primary patency of SFA PTA/S (broken down
prosthetic (asterisks within boxes). Error bars omitted for
of patients at risk at each time interval is shown below the fi
D, TASC D lesion; P, prosthetic femoropopliteal bypassStenoses are associated with better patency than occlusions,but if technical failures are excluded, patency rates are
similar between both lesions.
The national reporting standards for vascular proce-
dures define three categories of clinical success: anatomic,
hemodynamic, and clinical. A review of all published trials
of PTA with or without stenting in the femoropopliteal
arteries shows average patencies (anatomic success rates) of
71%, 59%, and 53% at 1, 3, and 5 years, respectively. Lesion
types were not routinely reported, but most studies con-
tained only A, B, and C lesions. The results of this series
(75% one- year, 60% three-year, and 52% five-year patency)
are grossly similar to these results. Technical success aver-
ages 90%, and complication rates up to 10% are seen. Our
technical success and complication rates are similar. It is
important to note that complications are not infrequent
with these procedures, even though they are viewed as
minimally invasive. Some form of a complication was seen
in 22% of the cases in this series. Most were minor (intimal
flap, dissection, groin hematoma), but some were not
sion type) compared with femoropopliteal bypass with
. All standard errors10% for data shown. The number
A, TASCA lesion; B, TASCB lesion;C,TASCC lesion;
tetrafluoroethylene, Dacron).by le
clarity
gure.(vessel occlusion, embolization, vessel perforation, bleed-
in.
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performing these procedures. Facility with pharmacologic
and mechanical thrombolysis is often needed to preserve
distal outflow vessels after clot fragments are sent down the
outflow vessels. Patients would require open thrombec-
tomy for removal of plaque fragments that emobolize and
occlude outflow vessels.
Although anatomic patency and hemodynamic success
are important, the primary reasons to perform an interven-
tion are symptom relief and long-term clinical success. In
our series, freedom from recurrent symptoms was seen in
87%, 72%, and 62% at 1, 4, and 6 years. This is in contrast
to the study by Karch at al,15 who demonstrated that only
40% of their patients were symptom free 4 years after SFA
angioplasty. Related to this is increased patient satisfaction
with minimally invasive approaches and fewer inpatient
hospital days needed after PTA/S, which might partially
Fig 2. Primary patency of SFA PTA/S (broken down by
(asterisks within boxes). Error bars omitted for clarity. All
at risk at each time interval is shown below the figure.A, T
D lesion; V, femoropopliteal bypass with autogenous veoffset the cost of the stents. Clinical failures are only par-tially related to anatomic patency of the treated area. Other
factors such as progression of disease in the inflow vessels,
in the treated vessel, and in the outflow tract are also
implicated. Fifty percent of these lesions are amenable to
additional percutaneous intervention. The findings that
clinical success appears to be higher than anatomic success
have been reported by others.16 When surgery is compared
with PTA for lesions appropriate for PTA, there are no
significant differences in hemodynamic outcomes between
bypass surgery and PTA.17,18 Studies of patients after sur-
gery (ie, iliofemoral or femoropopliteal bypass) have shown
that at 6 weeks, there is an improvement in resting ABI and
improved treadmill testing. However, up to 20% of patients
will be dissatisfied with their surgical outcome, even
though 50% of this dissatisfied subgroup will have a normal
postoperative ABI.
A weakness of the current study is that we did not break
n type) compared with femoropopliteal bypass with vein
ard errors10% for data shown. The number of patients
A lesion; B, TASC B lesion;C, TASC C lesion;D, TASClesio
stand
ASCthe open bypass patients down by lesion type. This would
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However, it is reasonable to infer thatmost of these patients
had TASC C and D lesions, and the overlap of the patency
curves is intriguing nonetheless. Other limitations of the
current study include the limited number of patients with
TASC B lesions available for follow-up beyond 6 to 12
months, and its retrospective, observational nature, so that
true cause-and-effect relationships can only be inferred.
Second, the study was nonrandomized, which implies that
unrecognized factors that might modify outcome have been
unequally distributed between the PTA/S patients and the
open surgical patients. Certainly, a large-scale randomized
clinical trial of open surgery versus PTA/S for TASC B and
TASCC lesions including aforementioned quality of life indi-
cators might be warranted to better determine the respective
roles of PTA/S versus surgery for these patients.
Finally, we must comment on the appropriateness of
Fig 3. Kaplan-Meier analysis showing freedom from rec
A and B lesions are compared to patients with TASC C a
of patients at risk at each time interval are shown in the t
was statistically significant.endoluminal therapy based on the findings of our study.Our patency data do suggest that for patients with TASC A
and B lesions, endoluminal therapy appears to be the
method of choice. For patients with TASCC andD lesions,
open bypass provides superior patency and must be given
first consideration. Factors that might make one select
endoluminal therapy for TASC C and D lesions include
infection at the proposed bypass site, medical comorbidities
that preclude open operation, or lack of autogenous vein
and below-knee reconstruction required. We agree that
quality of life factors and the concept that endoluminal
interventions usually do not alter surgical bypass plans must
be taken into account when deciding how to proceed with
these patients.
CONCLUSIONS
PTA/S of the SFA can be performed safely with ade-
quate technical success rates. Immediate symptom relief
t symptoms after PTA/S of the SFA. Patients with TASC
lesions. Error bars indicate standard errors. The number
elow the figure. The difference between the two groupsurren
nd D
able brates are high and are maintained. Results of the procedure
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results of PTA/S for TASC A and B lesions appeared
favorable to open femoropopliteal bypass. Successful
PTA/S was associated with a higher preoperative ABI and
the performance of angioplasty only. Failed PTA/S proce-
dures were associated with TASC C lesions and TASC D
lesions and the use of stents. Standard femoropopliteal
bypass appeared to be superior to PTA/S for TASC C and
D lesions. Improvements in stent designs or angioplasty
technique might ultimately improve these results. In this
series the presence of congestive heart failure was associated
with mortality in those patients undergoing PTA and/or S,
and congestive heart failure might represent a contraindi-
cation to endoluminal therapy in this setting.
We wish to acknowledge the help of Patricia Hackett
and Beth Sicard, both of whom assisted in the preparation
of this manuscript.
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Dr Joseph L. Mills (Tucson, Ariz). Did you look at the
quality of life outcome as opposed to just patency and limb salvage?
How did these patients do? A subset of that question is, when
patients with PTA of the SFA fail, how do they present? By that I
mean, if you look at a prosthetic femoropopliteal, there is a fairly
high incidence of the patient coming in with critical limb ischemia
when that graft fails. Does that also apply to an SFA angioplasty or
stent?
Your data would seem to indict stents as being a negative thing
to do for SFAs. But in your series, you only used stents when you
had a complication of the procedure with an angioplasty alone or
to treat long segment occlusions. So I don’t think that’s quite a fair
comparison. Do you have any information on what’s your current
practice as far as self-expanding stents, and what’s their role in the
treatment of superficial femoral aortoiliac occlusive disease, and
would that improve your results?
Dr ScottM. Surowiec.We did not do a detailed quality of life
analysis in terms of the percutaneous patients, so I can’t really
comment on that.
In terms of how the percutaneous failures presented, theyfollowing these patients and we were able to intervene on them
before their total percutaneous treatment failure.
In terms of the stents, I did try to look back and see what types
of stents were put in; however, we didn’t keep track of that in our
database. However, the placement of stents was operator-depen-
dent. Some people like to put them in primarily; however, in
general, they were used more in the C and D groups, and a lot of
the nitinol stents were used in that group as well. So for patients
with long segment disease we did have a preference for utilizing
nitinol stents.
Dr George Andros (Burbank, Calif). I think what I liked
most about the paper was that I assume all the angioplasties were
done by vascular surgeons, which I think is a quantum leap
forward. But, in essence, really, all you’ve done is validate what has
been written for 20 years in the TASC document. We really don’t
have any new information here from what I can tell. So I don’t
know what the take-home message is. Could you help me with
that?
Dr Surowiec. I think there is still debate in terms of TASC B
and TASC C lesions in terms of the appropriateness of percutane-
ous therapy. In terms of doing a detailed follow-up of patients who
JOURNAL OF VASCULAR SURGERY
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we found those to be very suitable for percutaneous therapy. So I
think the take-home message would be for TASC A and B lesions
that percutaneous therapy is a good option, and that surgical
patency rates are at least better for patients with TASC C and
TASC D lesions.
Dr Richard Cambria (Boston, Mass). This series mirrors
many of the tenets of our own series presented last September
before our regional New England Society for Vascular Surgery
meeting. I have one comment and one question.
The first comment is that the survival in your cohort, who have
a recognized risk factor for mortality, namely lower extremity
occlusive disease, is really extraordinary, and I wonder whether you
have any comment and/or explanation about that.
My second comment relates to the influence of stenting.
Presumably, could you give us some insight as to how stents were
used in the study to give us a little bit more information on how to
interpret that? Because, obviously, one interpretation could be
these were lesions that failed angioplasty and couldn’t be opened,
or more extensive lesions, and so forth.
My third comment/question relates to your conclusions. If
your only barometer or benchmark is the patency curve that has
become so dear to vascular surgeons, then your conclusion would
appear to be reasonable. However, if your conclusion is that you
don’t burn bridges by trying percutaneous therapy with a TASC B
or C lesion, and the patient can always have a bypass if it fails, then
for those patients in whom it works out, it is clearly a better
alternative than bypass. So I wouldn’t be too hasty in concluding
that TASC C and D lesions should not be treated with percutane-
ous therapy.
Dr Surowiec. In terms of the survival of the patients, we did
do survival analysis to determine that. Basically, we had 75%
survival at about 1 year, down to about 60% survival at 5 years.
In terms of why our survival rates are better, I think this might
be attributable to increased medical therapy and recognition that
risk factor modification is more important in the past few years.
In terms of the influence of stenting on the series, it’s a little bithighly operator-dependent. We did not determine the number of
primary stents versus secondary stents that were placed; however,
that is something that we could look into.
In terms of the TASC C and D lesions, in terms of doing these
procedures initially, that was kind of the influence to do this report,
and we really wanted to follow how well the C and D people really
do. At least during 12 to 24 months, they don’t do quite as well as
can be predicted. So that was kind of the motivation of the study.
Dr Robert Rutherford (Corpus Christi, Texas). Obviously,
from my point of view, it’s nice to see the TASC grading scheme
being utilized and have it come out and correlate so nicely with
success using the SVS success score. But I would tell you that one
of the most argued things in the TASC consensus was the assign-
ment of lesions to either TASC B or TASC C. We finally settled
that, but there was a little bloodshed over that particular thing.
They are a little arbitrary, and I think they might be changing.
My question really is, how much does your experience reflect
the use of these new nitinol self-expanding stents? Because my
impression is this whole thing is being opened up again for trials of
the new and improved stents. I wondered to what extent that your
experience, since you haven’t dated it in the abstract, at least,
reflects the use of these new stents.
Dr Surowiec. I can say, at least for the recent TASC D
experience that we have, that there is a very high proportion of
patients who did get the nitinol-type stents.
In terms of the TASC B and C classification, we do agree that
sometimes one of the difficult parts of the study was actually
classifying those lesions, and that the B’s and the C’s sometimes
were a bit confusing.
Dr Enrico Ascher (Brooklyn, NY). How do you assess the
technical success of your procedure in the operating room, by
using single plane, biplane angiography, or duplex scan? Because in
our experience, we found the duplex scan to bemuchmore reliable
than angiography.
Dr Surowiec. Our preference in the operating room is to
utilize angiography and basically as many planes as it takes to figurehard for me to interpret that because the placement of stents was out if things are okay.
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